Brief: AnaptysBio Q4 Net Income USD -42.211 Million
11/03/2024 20:15
Mar 11 (Reuters) - AnaptysBio Q4 income from operations USD -42.135 million. * Q4 operating expenses USD 51.14 million * Q4 collaboration revenue USD 9.005 million
Recent news on AnaptysBio
See all newsFirst Tracks Biotherapeutics up after $200 mln equity raise
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Brief: Anaptys Announces Second Quarter And Transitional Fiscal Year 2026 Financial Results And Provides Business Update
AnaptysBio Q2 collaboration revenue rises on higher Jemperli royalties